-
公开(公告)号：US20050267198A1
公开(公告)日：2005-12-01
申请号：US11193112
申请日：2005-07-29
IPC分类号： A61K9/28 , A61K9/50 , A61K31/40 , A61K31/401 , A61P3/06 , A61P9/00 , B01D9/02 , C07D207/34 , C07D405/06
CPC分类号： C07D207/34 , A61K9/282 , A61K9/5021 , C07D405/06
摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.
-
公开(公告)号：US20050261361A1
公开(公告)日：2005-11-24
申请号：US11193089
申请日：2005-07-29
IPC分类号： A61K9/28 , A61K9/50 , A61K31/40 , A61K31/401 , A61P3/06 , A61P9/00 , B01D9/02 , C07D207/34 , C07D405/06
CPC分类号： C07D207/34 , A61K9/282 , A61K9/5021 , C07D405/06
摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.
-
公开(公告)号：US20050261359A1
公开(公告)日：2005-11-24
申请号：US11192672
申请日：2005-07-29
IPC分类号： A61K9/28 , A61K9/50 , A61K31/40 , A61K31/401 , A61P3/06 , A61P9/00 , B01D9/02 , C07D207/34 , C07D405/06
CPC分类号： C07D207/34 , A61K9/282 , A61K9/5021 , C07D405/06
摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.
摘要翻译： 本发明提供了形式为VI，VIII，IX，X，XI和XII的阿托伐他汀的新形式及其制备方法以及制备阿托伐他汀形式I，II，IV，V和无定形阿托伐他汀的方法。
-
公开(公告)号：US20050197347A1
公开(公告)日：2005-09-08
申请号：US11018489
申请日：2004-12-20
IPC分类号： A61K31/496 , C07D417/12 , C07D417/14
CPC分类号： C07D417/12
摘要： Provided is a crystalline form of ziprasidone base and processes for its preparation.
摘要翻译： 提供齐拉西酮碱的结晶形式及其制备方法。
-
85.发明申请Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them 审中-公开昂丹司琼的新型晶体形式，其制备方法，药物，含有使用它们治疗恶心的新形式和方法的组合物公开(公告)号：US20050131045A1
公开(公告)日：2005-06-16
申请号：US10952165
申请日：2004-09-29
申请人： Judith Aronhime , Sandor Molnar , Csaba Szabo , Erzsebet Meszaros Sos , Szabolcs Salyi , Tivadar Tamas
发明人： Judith Aronhime , Sandor Molnar , Csaba Szabo , Erzsebet Meszaros Sos , Szabolcs Salyi , Tivadar Tamas
IPC分类号： C07D403/06 , A61K31/4178 , C07D43/02
CPC分类号： C07D403/06
摘要： Ondansetron crystalline Forms A, B, and B1 are useful in the treatment of nausea and vomiting. Some of the novel forms have uniquely high melting points. The novel forms are stable against thermally induced polymorphic transition from 30° C. up to their melting points.
摘要翻译： 昂丹司琼结晶形式A，B和B1可用于治疗恶心和呕吐。 一些新颖的形式具有独特的高熔点。 该新型形式对于30℃至其熔点的热诱导多晶型转变是稳定的。
-
86.发明申请Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms 失效阿伐他汀半钙的新型晶体形式及其制备方法以及制备其它形式的新方法公开(公告)号：US20050090542A1
公开(公告)日：2005-04-28
申请号：US10994142
申请日：2004-11-19
IPC分类号： A61K9/28 , A61K9/50 , A61K31/40 , A61K31/401 , A61P3/06 , A61P9/00 , B01D9/02 , C07D207/34 , C07D405/06
CPC分类号： C07D207/34 , A61K9/282 , A61K9/5021 , C07D405/06
摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.
摘要翻译： 本发明提供命名为形式VI，VIII，IX，X，XI和XII的阿托伐他汀的新形式及其制备方法以及制备阿托伐他汀形式I，II，IV，V和无定形阿托伐他汀的方法。
-
公开(公告)号：US20050038124A1
公开(公告)日：2005-02-17
申请号：US10947228
申请日：2004-09-23
申请人： Arina Ceausu , Anita Lieberman , Judith Aronhime
发明人： Arina Ceausu , Anita Lieberman , Judith Aronhime
IPC分类号： A61K20060101 , A61K31/165 , C07C20060101 , C07C315/02 , C07C315/06 , C07C317/44 , C30B7/00 , A61K31/16
CPC分类号： C07C317/44 , A61K31/165 , C07B2200/13 , C07C315/02 , C07C315/06 , C30B7/00 , C30B29/54
摘要： The present invention provides an improved process for preparing modafinil, whereby it may be isolated in high purity by a single crystallization. The process produces modafinil free of sulphone products of over-oxidation and other byproducts. The invention further provides new crystalline Forms II-VI of modafinil and processes for preparing them. Each of the new forms is differentiated by a unique powder X-ray diffraction pattern. The invention further provides pharmaceutical compositions containing novel modafinil Forms II-IV and VI.
摘要翻译： 本发明提供了一种制备莫达非尼的改进方法，从而可以通过单一结晶将其高纯度地分离出来。 该方法产生不含过氧化和其他副产物的砜类产物的莫达非尼。 本发明进一步提供了莫达非尼的新的晶型II-VI及其制备方法。 每种新形式都可以通过独特的粉末X射线衍射图进行区分。 本发明进一步提供了含有新型莫达非尼形式II-IV和VI的药物组合物。
-
88.发明申请Eluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them 失效Eluvastatin钠晶体形式，其制备方法，含有它们的组合物和使用它们的方法公开(公告)号：US20050032884A1
公开(公告)日：2005-02-10
申请号：US10872089
申请日：2004-06-18
IPC分类号： A61P3/06 , C07D209/24 , A61K31/225
CPC分类号： C07D209/12 , C07D209/24
摘要： Provided are polymorphic forms of fluvastatin sodium and processes for their preparation.
摘要翻译： 提供氟伐他汀钠的多晶型物质及其制备方法。
-
公开(公告)号：US06495721B1
公开(公告)日：2002-12-17
申请号：US09575634
申请日：2000-05-22
IPC分类号： C07C21142
CPC分类号： C07C209/68 , C07B2200/13 , C07C209/84 , C07C211/42 , C07C2602/10 , C07C2602/28 , C07C211/62
摘要： The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed.
摘要翻译： 本发明涉及盐酸舍曲林的II型及其制备方法。 根据本发明，盐酸舍曲林盐酸盐形式II可直接从舍曲林碱或舍曲林扁桃酸产生。 它也可以由盐酸舍曲林溶剂合物和水合物形式产生，并从新的溶剂体系中结晶。 还公开了含有舍曲林盐酸盐形式II的药物组合物和使用这种药物组合物的治疗方法。
-
90.发明授权公开(公告)号：US06482417B2
公开(公告)日：2002-11-19
申请号：US09789424
申请日：2001-02-21
IPC分类号： A61K900
摘要： Novel, stable pharmaceutical formulations for the oral administration of high purity torsemide modification II are disclosed. These formulations release high purity torsemide modification II in water at a constant and high purity rate, and the high purity torsemide modification II therein does not rearrange to torsemide modification I over time. Methods for their manufacture are also disclosed.
摘要翻译： 公开了用于口服高纯度托塞米德改性II的新型稳定的药物制剂。 这些制剂以恒定和高纯度的速率在水中释放高纯度的托塞米特改性II，并且其中的高纯度托塞米特改性II不随时间推移到托塞米特改性I. 还公开了其制造方法。
-
-
-
-
-
-
-
-
-
搜索结果
222 条记录 (耗时 0.063 秒)
